Question
tumor, endocrine-resistant metastatic breast cancer
TUMOR
Does treatment with alisertib restore fulvestrant sensitivity and improve tumor objective response rates (ORRs) compared with alisertib monotherapy in patients with endocrine-resistant metastatic breast cancer?